Use of glatiramer acetate between 2010–2015: effectiveness, safety and reasons to start GA as first or second line treatment in Swiss multiple sclerosis patients

Abstract Background Glatiramer acetate (GA) is one of the first therapies approved for multiple sclerosis (MS). We prospectively included and monitored drug-naïve and pre-treated MS patients who had been prescribed GA for 1 year, to investigate reasons for GA prescription, its effectiveness and safe...

وصف كامل

محفوظ في:
التفاصيل البيبلوغرافية
المؤلفون الرئيسيون: Chiara Zecca, Giulio Disanto, Rosaria Sacco, Gianna C. Riccitelli, Claudio Gobbi
التنسيق: Artigo
اللغة:Inglês
منشور في: BMC 2019-07-01
سلاسل:BMC Neurology
الموضوعات:
CIS
GA
Glatiramer acetate
Multiple sclerosis
Relapsing remitting
Therapy
الوصول للمادة أونلاين:http://link.springer.com/article/10.1186/s12883-019-1383-6
الوسوم: إضافة وسم
لا توجد وسوم, كن أول من يضع وسما على هذه التسجيلة!

مواد مشابهة